Asymmetrical dimethylarginine in renal disease: Limits of variation or variation limits? A systematic review

American Journal of Nephrology

Volumn 28, Issue 2, 2008, Pages 224-237

  Jacobi, Johannes ^a   Tsao, Philip S ^b,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asymmetrical dimethylarginine; Symmetric dimethylarginine

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; N(G),N(G) DIMETHYLARGININE; TELMISARTAN; VALSARTAN;

CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; ENZYME DEGRADATION; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADULT; AGED; ANIMALS; ARGININE; BIOLOGICAL MARKERS; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEPHROLOGY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 38349019064     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110092     Document Type: Review

References (64)

1. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
2. Kakimoto Y, Akazawa S: Isolation and identification of N-G,N-G- and N-G,N′-G-dimethyl-arginine, N-ε-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-δ-hydroxylysine from human urine. J Biol Chem 1970;245:5751-5758.
3. Vallance P, Leiper J: Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-1030.
4. McDermott JR: Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 1976;154:179-184.
5. Ogawa T, Kimoto M, Sasaoka K: Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987;148:671-677.
6. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343:209-214.
7. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-1459.
8. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E: Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996;11:2449-2452.
9. Marescau B, Nagels G, Possemiers I, De Broe ME, Becaus I, Billiouw JM, Lornoy W, De Deyn PP: Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997;46:1024-1031.
10. Al Banchaabouchi M, Marescau B, Possemiers I, D'Hooge R, Levillain O, De Deyn PP: NG, NG-dimethylarginine and NG, NGdimethylarginine in renal insufficiency. Pflügers Arch 2000;439:524-531.
11. Schmidt RJ, Baylis C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000;58:1261-1266.
12. Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G: Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int 2001;78(suppl):S14-S18.
13. Wahbi N, Dalton RN, Turner C, Denton M, Abbs I, Swaminathan R: Dimethylarginines in chronic renal failure. J Clin Pathol 2001;54:470-473.
14. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-176.
15. Schiel R, Franke S, Busch M, Muller A, Fleck C, Muller UA, Braun A, Stein G: Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency. Eur J Med Res 2003;8:283-291.
16. Saran R, Novak JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R, Handelman GJ, Barbato D, Weitzel W, D'Alecy LG, Rajagopalan S: Impact of vitamin E on plasma asymmetric dimethylarginine in chronic kidney disease: a pilot study. Nephrol Dial Transplant 2003;18:2415-2420.
17. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004;27:765-769.
18. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-2461.
19. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005;16:2449-2455.
20. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, ter Wee PM, van Guldener C: Plasma asymmetric dimethylarginine concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 concentration in patients with mild-to-moderate renal failure. Kidney Int 2005;68:2230-2236.
21. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006;47:42-50.
22. Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, Vural A, Zoccali C: ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006;70:781-787.
23. Busch M, Fleck C, Wolf G, Stein G: Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology? Amino Acids 2006;30:225-232.
24. Yilmaz MI, Saglam M, Sonmez A, Caglar K, Cakir E, Kurt Y, Eyileten T, Tasar M, Acikel C, Oguz Y, Vural A, Yenicesu M: Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif 2007;25:327-335.
25. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D: Symmetric dimethylarginine as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 2006;21:2446-2451.
26. Mendes Ribeiro AC, Roberts NB, Lane C, Yaqoob M, Ellory JC: Accumulation of the endogenous L-arginine analogue NG-monomethyl-L-arginine in human end-stage renal failure patients on regular haemodialysis. Exp Physiol 1996;81:475-481.
27. Kang ES, Tevlin MT, Wang YB, Chiang TM, Cardenas R, Myers LK, Acchiardo SR: Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period. Am J Med Sci 1999;317:9-21.
28. Anderstam B, Katzarski K, Bergstrom J: Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997;8:1437-1442.
29. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
30. Schmidt RJ, Domico J, Samsell LS, Yokota S, Tracy TS, Sorkin MI, Engels K, Baylis C: Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 1999;34:228-234.
31. Raj DS, Vincent B, Simpson K, Sato E, Jones KL, Welbourne TC, Levi M, Shah V, Blandon P, Zager P, Robbins RA: Hemodynamic changes during hemodialysis: role of nitric oxide and endothelin. Kidney Int 2002;61:697-704.
32. Osanai T, Fujiwara N, Saitoh M, Sasaki S, Tomita H, Nakamura M, Osawa H, Yamabe H, Okumura K: Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease. Blood Purif 2002;20:466-468.
33. Bergamini S, Vandelli L, Bellei E, Rota C, Manfredini P, Tomasi A, Albertazzi A, Iannone A: Relationship of asymmetric dimethylarginine to haemodialysis hypotension. Nitric Oxide 2004;11:273-278.
34. Mochizuki S, Ono J, Yada T, Ogasawara Y, Miyasaka T, Kimoto M, Kashihara N, Kajiya F: Systemic nitric oxide production rate during hemodialysis and its relationship with nitric oxide-related factors. Blood Purif 2005;23:317-324.
35. Morimoto H, Nakao K, Fukuoka K, Sarai A, Yano A, Kihara T, Fukuda S, Wada J, Makino H: Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant 2005;20:2775-2782.
36. Siroka R, Trefil L, Rajdl D, Racek J, Rusnakova H, Cibulka R, Eiselt J, Filipovsky J: Asymmetric dimethylarginine, homocysteine and renal function - is there a relation? Clin Chem Lab Med 2005;43:1147-1150.
37. Martens-Lobenhoffer J, Krug O, Bode-Boger SM: Determination of arginine and asymmetric dimethylarginine in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. J Mass Spectrom 2004;39:1287-1294.
38. Aslam S, Santha T, Leone A, Wilcox C: Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006;70:2109-2115.
39. Arese M, Strasly M, Ruva C, Costamagna C, Ghigo D, MacAllister R, Verzetti G, Tetta C, Bosia A, Bussolino F: Regulation of nitric oxide synthesis in uraemia. Nephrol Dial Transplant 1995;10:1386-1397.
40. Gomez-Fernandez P, Velasco G, Esteban J, Moreno VG, Guillen DA, Garcia Barroso C, Almaraz M: L-Arginine-nitric oxide pathway in hemodialysis (in Spanish). Nefrologia 2000;20: 262-268.
41. Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W: Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. Kidney Int 2001;78(suppl):S19-S24.
42. Kielstein JT, Boger RH, Bode-Boger SM, Martens-Lobenhoffer J, Lonnemann G, Frolich JC, Haller H, Fliser D: Low dialysance of asymmetric dimethylarginine - in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004;62:295-300.
43. Kalousova M, Kielstein JT, Hodkova M, Zima T, Dusilova-Sulkova S, Martens-Lobenhoffer J, Bode-Boger SM: No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif 2006;24:439-444.
44. Osanai T, Nakamura M, Sasaki S, Tomita H, Saitoh M, Osawa H, Yamabe H, Murakami S, Magota K, Okumura K: Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease. Kidney Int 2003;64:2291-2297.
45. Beerenhout CH, Luik AJ, Jeuken-Mertens SG, Bekers O, Menheere P, Hover L, Klaassen L, van der Sande FM, Cheriex EC, Meert N, Leunissen KM, Kooman JP: Pre-dilution online haemofiltration vs. low-flux haemodialysis: a randomized prospective study. Nephrol Dial Transplant 2005;20:1155-1163.
46. Chan CT, Harvey PJ, Boger R, Pierratos A, Floras JS: Dissociation between the short-term effects of nocturnal hemodialysis on endothelium dependent vasodilation and plasma ADMA. Arterioscler Thromb Vasc Biol 2005;25:2685-2686.
47. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117.
48. Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004;15:435-441.
49. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C: Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005;67:2330-2337.
50. Testa A, Spoto B, Tripepi G, Mallamaci F, Malatino L, Fatuzzo P, Maas R, Boeger R, Zoccali C: The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. J Hypertens 2005;23:1825-1830.
51. Spoto B, Benedetto FA, Testa A, Tripepi G, Mallamaci F, Maas R, Boeger RH, Zoccali C, Parlongo RM, Pisano A: Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease. Am J Hypertens 2005;18:1549-1555.
52. Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C: Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 2006;19:505-510.
53. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002;13:490-496.
54. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine in hemodialysis patients. Kidney Int 2002;62:339-345.
55. Kumagai H, Sakurai M, Takita T, Maruyama Y, Uno S, Ikegaya N, Kato A, Hishida A: Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am J Kidney Dis 2006;48:797-805.
56. Schmidt RJ, Yokota S, Tracy TS, Sorkin MI, Baylis C: Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol 1999;276:F794-F797.
57. Mittermayer F, Schaller G, Pleiner J, Vychytil A, Sunder-Plassmann G, Horl WH, Wolzt M: Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients. J Am Soc Nephrol 2005;16:1832-1838.
58. Yano A, Nakao K, Sarai A, Akagi S, Kihara T, Morimoto H, Nakamura A, Hiramatsu M, Nagake Y, Makino H: Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis. Nephrology (Carlton) 2005;10:576-582.
59. Cross JM, Donald A, Vallance PJ, Deanfield JE, Woolfson RG, MacAllister RJ: Dialysis improves endothelial function in humans. Nephrol Dial Transplant 2001;16:1823-1829.
60. Yilmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, Eyileten T, Yenicesu M, Acikel C, Oguz Y, Ozcan O, Bozlar U, Erbil K, Aslan I, Vural A: Endothelial functions improve with decrease in asymmetric dimethylarginine levels after renal transplantation. Transplantation 2005;80:1660-1666.
61. Cupisti A, Ghiadoni L, D'Alessandro C, Kardasz I, Morelli E, Panichi V, Locati D, Morandi S, Saba A, Barsotti G, Taddei S, Arnoldi A, Salvetti A: Soy protein diet improves endothelial dysfunction in renal transplant patients. Nephrol Dial Transplant 2007;22:229-234.
62. Soveri I, Lind L, Wikstrom B, Zilmer M, Zilmer K, Fellstrom B: Improvement in central arterial pressure waveform during hemodialysis is related to a reduction in asymmetric dimethylarginine levels. Nephron Clin Pract 2007;106:c180-c186.
63. Grooteman MP, Wauters IM, Teerlink T, Twisk JW, Nube MJ: Plasma Dimethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied. Blood Purif 2007;25:281-289.
64. Billecke SS, Kitzmiller LA, Northrup JJ, Whitesall SE, Kimoto M, Hinz AV, D'Alecy LG: Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am J Physiol 2006;291:H1788-H1796.